LLE Therapeutics

LLE Therapeutics is a pre-clinical stage biotechnology company focused on developing novel treatments for Age-related Macular Degeneration (AMD). The company's approach is based on the Leaky Lipid Envelope (LLE) hypothesis, which suggests that the breakdown of lipid barriers in the eye is a key driver of retinal disease progression. LLE Therapeutics is currently advancing its lead program, LLE-101, to address the underlying causes of geographic atrophy and vision loss. As a project-focused company (PFC) backed by TVM Capital Life Science, LLE Therapeutics operates with a lean structure to efficiently reach clinical proof-of-concept. The company's technology originated from research conducted at the University of Utah's Moran Eye Center. The goal is to provide a disease-modifying therapy that can preserve vision in patients with advanced retinal degeneration.